血液和骨髓移植临床研究网络 2021 年科学研讨会：展望未来，网络迎来成立 20 周年。
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.
机构信息
Baylor College of Medicine, Houston, Texas.
University of Pennsylvania, Philadelphia, Pennsylvania.
出版信息
Transplant Cell Ther. 2021 Nov;27(11):885-907. doi: 10.1016/j.jtct.2021.08.016. Epub 2021 Aug 27.
Abstract
In 2021 the BMT CTN held the 4th State of the Science Symposium where the deliberations of 11 committees concerning major topics pertinent to a particular disease, modality, or complication of transplant, as well as two committees to consider clinical trial design and inclusion, diversity, and access as cross-cutting themes were reviewed. This article summarizes the individual committee reports and their recommendations on the highest priority questions in hematopoietic stem cell transplant and cell therapy to address in multicenter trials.
摘要
2021 年，BMT CTN 举办了第四次科学现状研讨会，会上审议了 11 个委员会关于与移植相关的特定疾病、治疗方式或并发症的主要议题，以及两个委员会关于临床试验设计以及纳入、多样性和可及性等跨领域主题的审议结果。本文总结了各个委员会报告的内容及其对造血干细胞移植和细胞治疗中多中心试验中应优先解决的关键问题的建议。
相似文献
1
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.
Transplant Cell Ther. 2021 Nov;27(11):885-907. doi: 10.1016/j.jtct.2021.08.016. Epub 2021 Aug 27.
2
Blood and Marrow Transplant Clinical Trials Network: progress since the State of the Science Symposium 2007.
Biol Blood Marrow Transplant. 2014 Feb;20(2):149-53. doi: 10.1016/j.bbmt.2013.11.006. Epub 2013 Nov 12.
3
Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report From the BMT CTN Patient and Caregiver Advocacy Task Force.
Transplant Cell Ther. 2023 Jan;29(1):5-9. doi: 10.1016/j.jtct.2022.10.016. Epub 2022 Oct 23.
4
Blood and marrow transplant clinical trials network (BMT CTN): addressing unanswered questions.
Biol Blood Marrow Transplant. 2007 Mar;13(3):257-62; discussion 255-6. doi: 10.1016/j.bbmt.2006.11.017.
5
Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).
Biol Blood Marrow Transplant. 2015 Jan;21(1):4-7. doi: 10.1016/j.bbmt.2014.09.017. Epub 2014 Sep 30.
6
The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research.
Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S1-S2. doi: 10.1038/bmt.2008.101.
7
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007.
Biol Blood Marrow Transplant. 2007 Nov;13(11):1268-85. doi: 10.1016/j.bbmt.2007.08.005.
8
Designing and conducting a clinical trial in blood and marrow transplantation.
Best Pract Res Clin Haematol. 2023 Jun;36(2):101471. doi: 10.1016/j.beha.2023.101471. Epub 2023 May 11.
9
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2016 Oct;22(10):1747-1757. doi: 10.1016/j.bbmt.2016.07.003. Epub 2016 Jul 11.
10
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
Cochrane Database Syst Rev. 2014 Apr 20;2014(4):CD010189. doi: 10.1002/14651858.CD010189.pub2.
引用本文的文献
1
Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice.
Blood Adv. 2025 Sep 9;9(17):4448-4457. doi: 10.1182/bloodadvances.2024015405.
2
Challenges and Opportunities in the Care of Hematopoietic Cell Transplant Survivors in the Modern Era.
Adv Exp Med Biol. 2025;1475:209-226. doi: 10.1007/978-3-031-84988-6_12.
3
Towards graft--host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia.
Haematologica. 2025 Aug 1;110(8):1693-1701. doi: 10.3324/haematol.2024.286544. Epub 2025 May 29.
4
How I treat postimmunotherapy relapsed B-ALL.
Blood. 2025 Jan 2;145(1):64-74. doi: 10.1182/blood.2024024517.
5
Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation.
Transplant Cell Ther. 2024 Oct;30(10):1027.e1-1027.e14. doi: 10.1016/j.jtct.2024.07.009. Epub 2024 Jul 20.
6
Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor.
Blood Adv. 2024 Feb 13;8(3):758-765. doi: 10.1182/bloodadvances.2023011814.
7
Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia.
Haematologica. 2024 Feb 1;109(2):657-660. doi: 10.3324/haematol.2023.284022.
8
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?
Blood Rev. 2023 Jul;60:101079. doi: 10.1016/j.blre.2023.101079. Epub 2023 Apr 7.
9
How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL.
Blood. 2023 Mar 16;141(11):1251-1264. doi: 10.1182/blood.2022016937.
10
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.
Lancet Haematol. 2022 Sep;9(9):e660-e669. doi: 10.1016/S2352-3026(22)00206-X. Epub 2022 Jul 27.
本文引用的文献
1
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.
Lancet Haematol. 2021 Mar;8(3):e185-e193. doi: 10.1016/S2352-3026(20)30429-4. Epub 2021 Jan 19.
2
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
J Clin Oncol. 2021 Jun 10;39(17):1865-1877. doi: 10.1200/JCO.20.01086. Epub 2021 Jan 15.
3
Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.
J Clin Oncol. 2021 Feb 10;39(5):534-544. doi: 10.1200/JCO.20.01623. Epub 2021 Jan 12.
4
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Lancet Haematol. 2021 Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22.
5
Bispecifics, trispecifics, and other novel immune treatments in myeloma.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):264-271. doi: 10.1182/hematology.2020000110.
6
The evolution of NK cell immunotherapy for hematologic malignancies: A historical and contemporary perspective.
Semin Hematol. 2020 Oct;57(4):165-166. doi: 10.1053/j.seminhematol.2020.11.005. Epub 2020 Nov 13.
7
Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia.
Clin Cancer Res. 2021 Feb 1;27(3):843-851. doi: 10.1158/1078-0432.CCR-20-2809. Epub 2020 Nov 4.
8
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Blood Adv. 2020 Nov 10;4(21):5414-5424. doi: 10.1182/bloodadvances.2020003092.
9
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Nat Med. 2020 Dec;26(12):1852-1858. doi: 10.1038/s41591-020-1089-8. Epub 2020 Oct 26.
10
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
JAMA Oncol. 2020 Dec 1;6(12):1890-1899. doi: 10.1001/jamaoncol.2020.4600.
Zotero 插件